Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Zydus Lifesciences Ltd (ZYDU)

NSE
Currency in INR
Disclaimer
948.00
-3.25(-0.34%)
Closed

ZYDU Comments

Update ZYDUSLIFE Revised Stop Loss 637 from 624
Update ZYDUSLIFE from 640 from 624
Delivery Buy ZYDUSLIFE above 647 Stop Loss 624 Target 670+
sell he will down again 520
next target 425-450 🎯
next target 350
very nice results
loose drastically
Next target would be 435
Tomorrow make/break
haha hojaega
cadila ka khun kb kholega
kb nrega cadilla plz tell
cadila result is very good. bay 495 cadila target 550++++ aaj hi chala jayega
View on this stock
cadila is performing lower lto why? will touch tgt 586 reply bery excited share 586 650
cadila is performing lower lto why? will touch tgt 625. reply
Pm modi very excited on new vaccine approval...India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed.
above one is comment by PM Modi on new Corona vaccine approved by DCGA
cadila vaccine approve DCGI. Monday 600+++Thursday 700+++++shorter shot opening bell Monday
Cadila result is good. Buy cadila target 605
What is the about opinion on cadila
Cadila ka result kaisa hai?
Buy ROUTE at 2070 target 2300++
Buy HINDCOPPER at 145-147 Target 170 to 200++
cadila got drug approval from usfda 👌👇
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.